Clearside Biomedical (NASDAQ:CLSD) announced its quarterly earnings results on Thursday. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12), Fidelity Earnings reports.

Shares of NASDAQ CLSD traded down $0.14 during mid-day trading on Friday, reaching $1.84. 707,532 shares of the company were exchanged, compared to its average volume of 703,408. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.94 and a current ratio of 7.94. The stock has a market cap of $70.13 million, a PE ratio of -0.79 and a beta of -3.98. Clearside Biomedical has a twelve month low of $1.83 and a twelve month high of $15.33.

A number of analysts have commented on the stock. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Wedbush set a $29.00 price target on shares of Clearside Biomedical and gave the company a “buy” rating in a research note on Wednesday, August 8th. Cowen cut shares of Clearside Biomedical from an “outperform” rating to a “market perform” rating in a research note on Monday, November 5th. BidaskClub cut shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Friday, July 20th. Finally, Laidlaw assumed coverage on shares of Clearside Biomedical in a research note on Monday, July 16th. They issued a “buy” rating and a $18.00 price target for the company. Three analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Clearside Biomedical presently has an average rating of “Hold” and a consensus price target of $12.71.

Several hedge funds and other institutional investors have recently bought and sold shares of CLSD. Voya Investment Management LLC bought a new position in Clearside Biomedical during the second quarter worth about $123,000. BlackRock Inc. increased its position in Clearside Biomedical by 53.1% during the second quarter. BlackRock Inc. now owns 1,859,948 shares of the company’s stock worth $19,883,000 after acquiring an additional 645,292 shares during the period. Point72 Asset Management L.P. bought a new position in Clearside Biomedical during the second quarter worth about $2,138,000. Alps Advisors Inc. bought a new position in Clearside Biomedical during the second quarter worth about $496,000. Finally, GSA Capital Partners LLP bought a new position in Clearside Biomedical during the second quarter worth about $534,000. Institutional investors own 62.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://theolympiareport.com/2018/11/10/clearside-biomedical-clsd-issues-earnings-results.html.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

See Also: Does the discount rate affect the economy?

Earnings History for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.